Long-Term Effects of Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of \textit{S. pneumoniae}, \textit{S. aureus}, \textit{H. influenzae} and \textit{M. catarrhalis}

Judith Spijkerman\textsuperscript{1,2}, Sabine M. P. J. Prevaes\textsuperscript{1,2}, Elske J. M. van Gils\textsuperscript{1,2}, Reinier H. Veenhoven\textsuperscript{2}, Jacob P. Bruin\textsuperscript{3}, Debby Bogaert\textsuperscript{1}, Alienke J. Wijmenga-Monsuur\textsuperscript{4}, Germie P. J. M. van den Dobbelsteen\textsuperscript{4}, Elisabeth A. M. Sanders\textsuperscript{1}\textsuperscript{*}

\textsuperscript{1}Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Center, Utrecht, The Netherlands, \textsuperscript{2}Research Center Linnaeus Institute, Spaarne Hospital, Hoofddorp, The Netherlands, \textsuperscript{3}Regional Laboratory of Public Health, Haarlem, The Netherlands, \textsuperscript{4}Vaccinology Unit, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

\textbf{Abstract}

\textbf{Background:} Shifts in pneumococcal serotypes following introduction of 7-valent pneumococcal conjugate vaccine (PCV-7) may alter the presence of other bacterial pathogens co-inhabiting the same nasopharyngeal niche.

\textbf{Methodology/Principal Findings:} Nasopharyngeal prevalence rates of \textit{S. pneumoniae}, \textit{S. aureus}, \textit{H. influenzae} and \textit{M. catarrhalis} were investigated before, 3 and 4.5 years after introduction of PCV-7 in the national immunisation program in children at 11 and 24 months of age, and parents of 24-month-old children (n=330/group) using conventional culture methods. Despite a virtual disappearance of PCV-7 serotypes over time, similar overall pneumococcal rates were observed in all age groups, except for a significant reduction in the 11-month-old group (adjusted Odds Ratio after 4.5 years 0.48, 95\% Confidence Interval 0.34–0.67). Before, 3 and 4.5 years after PCV-7 implementation, prevalence rates of \textit{S. aureus} were 5\%, 9\% and 14\% at 11 months of age (3.59, 1.90–6.79) and 20\%, 32\% and 34\% in parents (1.96, 1.36–2.83), but remained similar at 24 months of age, respectively. Prevalence rates of \textit{H. influenzae} were 46\%, 65\% and 65\% at 11 months (2.22, 1.58–3.13), 52\%, 73\% and 76\% at 24 months of age (2.68, 1.88–3.82) and 23\%, 30\% and 40\% in parents (2.26, 1.58–3.33), respectively. No consistent changes in \textit{M. catarrhalis} carriage rates were observed over time.

\textbf{Conclusions/Significance:} In addition to large shifts in pneumococcal serotypes, persistently higher nasopharyngeal prevalence rates of \textit{S. aureus} and \textit{H. influenzae} were observed among young children and their parents after PCV-7 implementation. These findings may have implications for disease incidence and antibiotic treatment in the post-PCV era.

\textbf{Citation:} Spijkerman J, Prevaes SMPJ, van Gils EJM, Veenhoven RH, Bruin JP, et al. (2012) Long-Term Effects of Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of \textit{S. pneumoniae}, \textit{S. aureus}, \textit{H. influenzae} and \textit{M. catarrhalis}. PLoS ONE 7(6): e39730. doi:10.1371/journal.pone.0039730

\textbf{Editor:} Eliane Namie Miyaji, Instituto Butantan, Brazil

\textbf{Received} April 5, 2012; \textbf{Accepted} May 25, 2012; \textbf{Published} June 25, 2012

\textbf{Copyright:} © 2012 Spijkerman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\textbf{Funding:} This work was supported by the Dutch Ministry of Health the Netherlands. Grant support for pneumococcal surveillance and serotyping was provided by Wyeth-Pfizer Vaccines (grant number WS847078/GIPIHP_RG_20101022T1552, 0887X1-4598). Both funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

\textbf{Competing Interests:} The authors have read the journal's policy and have the following conflicts: RHV has received research support from GlaxoSmithKline and Pfizer. EAMS has received unrestricted grant support for vaccine studies and consulting fees for GlaxoSmithKline and Pfizer-Wyeth for vaccine studies and consulting fees for GlaxoSmithKline. BD declares to have received consulting fees from Pfizer. All other authors have declared that no competing interests exist.

* E-mail: l.sanders@umcutrecht.nl

\textbf{Introduction}

The 7-valent pneumococcal conjugate vaccine (PCV-7; Prevenar\textsuperscript{TM}, Pfizer) prevents nasopharyngeal acquisition of 7 paediatric serotypes in children and transmission to others [1,2]. This results in protection against PCV-7 serotype disease in all age groups [3–5]. The vacant nasopharyngeal niche in PCV-7 vaccinated children is immediately occupied by non-PCV-7 groups [3–5]. The vacant nasopharyngeal niche in PCV-7 vaccinated children is immediately occupied by non-PCV-7 groups [3–5]. This results in protection against PCV-7 serotype disease in all age groups [3–5].

Previous reports have demonstrated potential associations between pneumococcal presence in the nasopharynx, in particular vaccine serotypes, and bacteria like \textit{H. influenzae}, \textit{M. catarrhalis} or \textit{S. aureus} co-inhabiting the same ecological niche [6–8]. This has raised the concern that shifts in pneumococcal serotypes after PCV-7 vaccination may facilitate the involvement of other major contributors to respiratory, as demonstrated in three otitis media efficacy trials [9–11], or invasive disease in childhood [12–14]. A temporary increase in \textit{S. aureus} nasopharyngeal carriage at one year of age after PCV-7 vaccinations at 2, 4 and 11 months was previously reported in a randomized controlled trial [15]. Several years of nationwide PCV-7 vaccine pressure might enhance shifts in the bacterial ecosystem in infants. Young children are an important reservoir and major source of transmission of bacteria to the whole community [14,16,17]. Therefore, the aim of this
study was to investigate the long-term effects of PCV-7 on nasopharyngeal carriage of *S. pneumoniae, S. aureus, H. influenzae* and *M. catarrhalis* in healthy PCV-7 vaccinated children and their unvaccinated parents in the Netherlands.

**Methods**

**Ethics statement**

Both cross-sectional studies were approved by an acknowledged ethics committee from the Netherlands (CCMO; Centrale Commissie Mensgebonden Onderzoek, available at: http://www.ccmo-omline.nl). Parents of children living in the western part of the Netherlands were provided with written information about the study and asked to participate. Written informed consent was obtained from all parents and the procedures followed were in accordance with European Statements for Good Clinical Practice and the Declaration of Helsinki of the World Medical Association.

**Study design**

PCV-7 was implemented in the national immunization program (NIP) for all infants born after 31 March 2006 at 2, 3, 4 and 11 months of age without a catch-up campaign for older children. Traditionally, PCV-7 vaccine uptake reached almost 95% [18]. Two subsequent cross-sectional carriage studies of similar design were conducted to evaluate nasopharyngeal bacterial carriage after introduction of PCV-7 in the national immunization program (NIP): 1) 3 years post-PCV-7 (February through July 2009) and 2) 4.5 years post-PCV-7 (September 2010 through January 2011). In both cross-sectional study cases, nasopharyngeal bacterial carriage was evaluated by means of home visits in two age-cohorts of healthy children vaccinated according to the Dutch NIP: 1) 11-month-old children after 3 primary doses but who had not yet, or had within the last week, obtained the booster dose at 11 months, and 2) 24-month-old children after four doses. Additionally, nasopharyngeal samples were collected from one of the parents of each 24-month-old child. Exclusion criteria were known or suspected immunodeficiency, craniofacial or chromosomal abnormalities, coagulation disorders and use of anticoagulant medication. Data of the vaccinated children cohorts and their parents were compared with data from PCV-7 unvaccinated children at the age of 12 and 24 months and parents of 24-month-old children derived from a previous, randomized controlled trial that had started in the Netherlands well before national PCV7 implementation for infants (NCT00189020) [19]. In this trial, children had been included at the age of 6 weeks between July 2005 and February 2006 and were followed-up until 24 months of age.

**Procedures**

Transnasal nasopharyngeal samples were obtained from children and parents by trained study personnel with a nylon flocked rigid sterile swab under direct observation of the posterior pharynx, as the pneumococcal yield is known to be higher in adults when taking both samples [21]. After sampling, all swabs were directly inoculated in liquid Amies medium and plated within 24 hours. All the swabs of the three studies were processed by the same laboratory and cultured for presence of *S. pneumoniae, S. aureus, H. influenzae* and *M. catarrhalis* according to standard bacteriological procedures for conventional culture. One pneumococcal colony per plate was subcultured and serotyped by Quellung reaction using type-specific antisera from the Statens Serum Institute (Copenhagen, Denmark). In a post-hoc analysis, the presence of methicillin resistance was determined in a random sample of 30 (65%) of the *S. aureus* strains obtained from children at 11 months of age 4.5 years after PCV-7 implementation by using disk diffusion method for cefoxitine and by detection of the mecA gene [22].

**Covariates**

Parents of the participating children completed a brief survey on the following possible predictors of nasopharyngeal bacterial carriage: age, sex, season of sampling, antibiotic use within one month prior to sampling, symptoms of a respiratory tract infection and/or acute otitis media during sampling, presence of siblings in the household, day care attendance of the participating child, passive smoke exposure indoors, active smoking of the participating parent.

**Statistical analyses**

This study was designed to demonstrate changes in pneumococcal carriage after PCV-7 implementation requiring 330 persons per group as described previously (4). Assessment of the effects of PCV-7 on carriage of *H. influenzae, M. catarrhalis* and *S. aureus* were designated secondary outcomes. Given estimated prevalence rates of 49%, 64% and 3% for *H. influenzae, M. catarrhalis* and *S. aureus* in children based on previous reports [13,20], a sample size of 330 could detect with 80% power and a 2-sided t of 0.05 an increase of 10%, 9% and 6%, respectively. Differences in prevalence rates were tested using 2-sided χ2 or Fisher’s exact test, where appropriate. P-values <0.05 were considered significant. Multivariate analysis with backward LR binary logistic regression modelling was used to obtain adjusted estimates of the association between the outcomes and intervention as given by adjusted odds ratio’s (aOR) and their corresponding 95% confidence intervals (95% CI). All measured possible confounders were entered in this model and removed when p-value was >0.10. To obtain the aOR for the intervention effect in case the intervention variable was not included in the final model (i.e. p-value >0.10), this variable combined with all remaining variables of the final backward LR model were entered in a binary logistic regression model without selection (SPSS version 17.0).

**Results**

Baseline characteristics of children and their parents before, 3 and 4.5 years after implementation of PCV-7 in the NIP are shown in Table 1. The most noticeable difference among all three time-points is the season of sampling.

**Carriage of *S. pneumoniae***

Three years after PCV-7 implementation (post-PCV7), a nearly complete eradication of PCV-7 serotype carriage in children and adults was demonstrated, resulting in significant declines in overall pneumococcal carriage at 11 and 24 months of age and similar carriage rates in parents [2]. After 4.5 years, PCV-7-serotypes as well as cross-reactive serotype 6A were found only incidentally in all age groups (Table S1). Compared to pre-PCV7, overall pneumococcal prevalence rates had remained significantly lower at 11 months of age after 4.5 years (adjusted Odds Ratio (aOR) 0.48, 95% Confidence Interval 0.34–0.67), but had risen to similar levels at 24 months of age and in parents (Table 2). Serotype 19A became the predominant colonizer in all age groups, followed by serotypes 6C, 15 B/C and 11A (Table S1).
Carriage of S. aureus

The prevalence of S. aureus was significantly higher in children at 11 months of age (aOR 1.97, 1.04–3.72) and in parents (1.85, 1.36–2.83) 3 years post-PCV7 compared to pre-PCV7. After 4.5 years, a further increase in the prevalence of S. aureus was observed at 11 months of age (2.26, 1.58–3.33) compared to pre-PCV7 and results persisted in parents. No changes in S. aureus carriage were observed in children at 24 months of age after 3 and 4.5 years post-PCV7 (Table 2). No methicillin resistance was detected in tested isolates (n = 30) obtained from 11-month-old children 4.5 years post-PCV7. No methicillin resistance was observed at 11 months of age (2.26, 1.58–3.33) compared to pre-PCV7 (Table 2).

Carriage of H. influenzae

The prevalence of H. influenzae was significantly higher in children at 11 months (aOR 2.69, 1.90–3.80) and 24 months (2.70, 1.91–3.82) and parents (1.49, 1.03–2.14) after 3 years of PCV-7 implementation compared to pre-PCV7. After 4.5 years, higher levels persisted in children and a further increase in prevalence of H. influenzae was observed in parents (2.69, 1.90–3.80) compared to pre-PCV7. After 4.5 years, the prevalence of H. influenzae remained unchanged in children and parents 3 years post-PCV7 as compared to pre-PCV7. After 4.5 years, the prevalence of M. catarrhalis remained similar at 11 months of age, but was significantly higher in children at 24 months of age (aOR 1.75, 1.18–2.61) and in parents (2.54, 1.59–4.08) compared to pre-PCV7 (Table 2).

Carriage of M. catarrhalis

The prevalence of M. catarrhalis remained unchanged in children and parents 3 years post-PCV7 as compared to pre-PCV7. After 4.5 years, the prevalence of M. catarrhalis remained similar at 11 months of age, but was significantly higher in children at 24 months of age (aOR 1.75, 1.18–2.61) and in parents (2.54, 1.59–4.08) compared to pre-PCV7 (Table 2).

Table 1. Characteristics of children and their parents before, 3 and 4.5 years after implementation of PCV-7 in the Netherlands.

|                          | 11 months |                          | 24 months |                          |
|--------------------------|-----------|--------------------------|-----------|--------------------------|
|                          | Pre-PCV7 | 3yr Post | 4.5yr Post | Pre-PCV7 | 3yr Post | 4.5yr Post |
|                          | no. (%)  | no. (%)  | no. (%)    | no. (%)  | no. (%)  | no. (%)    |
| Children                 |          |          |            |          |          |            |
| Male sex                 | n = 319  | n = 329  | n = 330    | n = 321  | n = 330  | n = 330    |
| Mean age in months (SD)  | 12.0 (0.3)| 10.9 (0.3)| 10.7 (0.4) | 24.2 (0.6)| 24.0 (0.3)| 23.8 (0.5) |
| Presence of siblings <5yr| 126 (40) | 84 (26)  | 145 (44)   | 127 (40) | 135 (41) | 154 (47)   |
| Day care attendance      | 208 (65) | 226 (69) | 222 (67)   | 224 (70) | 233 (71) | 259 (79)   |
| Passive smoke exposure   | 21 (7)   | 5 (2)    | 9 (3)      | 26 (8)   | 16 (5)   | 12 (4)     |
| Signs of URTI and/or OMA | 95 (30)  | 95 (29)  | 112 (34)   | 82 (26)  | 69 (21)  | 114 (35)   |
| Antimicrobial drug use    | 20 (6)   | 24 (7)   | 27 (8)     | 10 (3)   | 23 (7)   | 15 (5)     |
| Period of sampling       |          |          |            |          |          |            |
| October-March            | n = 296  | n = 324  | n = 326    | n = 296  | n = 324  | n = 326    |
| April-September          | 109 (37) | 127 (39) | 146 (44)   | 109 (37) | 127 (39) | 146 (44)   |
|                          |          |          |            |          |          |            |
| Parents                  |          |          |            |          |          |            |
| Male sex                 | n = 156  | n = 181  | n = 173    | n = 155  | n = 187  | n = 171    |
| Mean age in years (SD)   | 34.7 (4.9)| 35.1 (4.4)| 35.3 (4.5) | 35.1 (4.4)| 35.3 (4.5)| 35.3 (4.5) |
| Active smoking           | 40 (14)  | 34 (11)  | 41 (13)    | 40 (14)  | 34 (11)  | 41 (13)    |
| Antimicrobial drug use    | 9 (3)    | 20 (6)   | 16 (5)     | 9 (3)    | 20 (6)   | 16 (5)     |

Note. PCV-7: 7-valent pneumococcal conjugate vaccine. SD: standard deviation. *Defined as use of oral or intravenous antibiotics within 1 month before sample was taken.

Discussion

This is the first study that describes the long-term follow-up of nasopharyngeal carriage of S. aureus, H. influenzae and M. catarrhalis next to S. pneumoniae after introduction of PCV-7 in the NIP. In addition to the virtual elimination of PCV-7 serotypes, we demonstrated significantly higher S. aureus carriage rates in children by the end of the first year of life and in the parents group. For H. influenzae, significantly higher prevalence rates were detected among children at both 11 and 24 months of age and in parents. Shifts in nasopharyngeal carriage profiles of these bacteria may affect disease incidence due to these pathogens in PCV-7 vaccinated children as well as in the population. Moreover, increased nasopharyngeal carriage may lead to increased exposure of strains to antibiotics, which may subsequently lead to selection of resistant ones [23].

The results on S. aureus carriage are consistent with a previous randomized controlled trial that demonstrated a doubled rate of S. aureus carriage in healthy children at 12 months of age after 2+1 doses of PCV-7 and in parents as compared to unvaccinated controls [15]. Similar to our present study, in this trial the impact of PCV-7 on S. aureus carriage in children was limited to young children around 12 months of age and no longer present at 18 or 24 months of age. This indicates an effect on S. aureus carriage when carriage dynamics are at their peak, around PCV-7 vaccinations in infancy, and disappearing later after non-PCV-7 serotypes have filled in the gap or by age-dependent maturation of the immune system in the second year of life. The impact of pneumococcal vaccinations on S. aureus presence is also in line with a randomized controlled trial where an increased rate of S. aureus culture–positive acute otitis media (AOM) was demonstrated...
shortly after pneumococcal vaccinations in children suffering from recurrent AOM, who were PCV-7-vaccinated followed by the 23-valent polysaccharide vaccine [11].

In support of these findings, several studies from other sites have also reported a negative interaction between *S. pneumoniae*, in particular PCV-7-serotypes, and *S. aureus* carriage in healthy children [6-24] but also during severe pneumonia illness in HIV-negative children [25]. In contrast to these studies, two observational studies performed after introduction of PCV-7, one in children with acute otitis media and one in primary-care visiting observational studies performed after introduction of PCV-7, one HIV-negative children [25]. In contrast to these studies, two valent polysaccharide vaccine [11].

The observed increase in nasopharyngeal carriage of *S. aureus* is worrisome as this is a known risk factor for infection [14,31], and especially young children in first year of life are vulnerable for worrisome as this is a known risk factor for infection [14,31], and but rarely detected in infants [8,30].

### Table 2. Frequencies of nasopharyngeal carriage and (adjusted) odds ratios of *S. pneumoniae*, *S. aureus*, *H. influenzae* and *M. catarrhais* in children and parents before, 3 and 4.5 years after PCV-7 implementation.

| Pre-PCV7 | 3yr Post | 4.5yr Post | 3yr Post vs. Pre-PCV7 | 4.5yr Post vs. Pre PCV7 | 4.5yr Post vs. 3yr Post PCV7 |
|----------|----------|-----------|-----------------------|-------------------------|-----------------------------|
|          | no. (%)  | no. (%)   | OR (95% CI)            | OR (95% CI)             | OR (95% CI)                 |
| S. pneumoniae | n = 319 | n = 329 | n = 330 |                          |                            |                            |
| PCV-7-serotypes | 214 (67) | 154 (47) | 173 (52) | 0.43 (0.31–0.59)          | 0.43 (0.30–0.60)           | 0.54 (0.39–0.74)           |
| Non-PCV-7-serotypes | 122 (38) | 25 (8) | 10 (3) | 0.13 (0.08–0.21)          | 0.14 (0.09–0.23)           | 0.05 (0.03–0.10)           |
| *S. aureus* | 16 (5) | 31 (9) | 46 (14) | 1.97 (1.06–3.68)          | 1.97 (1.04–3.72)           | 3.07 (1.70–5.54)           |
| *H. influenzae* | 146 (46) | 212 (64) | 213 (65) | 0.07 (0.02–0.29)          | 0.07 (0.02–0.29)           | 0.24 (0.10–0.56)           |
| *M. catarrhais* | 218 (68) | 210 (64) | 251 (76) | 0.82 (0.59–1.13)          | 0.89 (0.62–1.27)           | 1.47 (0.94–2.32)           |

Note. PCV-7: all serotypes included in 7-valent pneumococcal conjugate vaccine. Non-PCV-7: all serotypes not included in 7-valent pneumococcal conjugate vaccine. OR: odds ratio; CI: confidence interval. aOR: adjusted odds ratio. All (a)OR-values are based on comparison with cohort as indicated. *In* children, OR-values were adjusted by multivariate analysis for sex, months of sampling, presence of siblings <5yr and day care attendance, antibiotic use, passive smoke exposure and the presence of URTI and/or OMA using binary logistic regression with backward LR. *In* parents, OR-values were adjusted by multivariate analysis for sex, months of sampling, antibiotic use, active smoking, presence of siblings <5yr other than participating child and day care attendance of their participating child.

doi:10.1371/journal.pone.0039730.t002
results, long-term follow-up of staphylococcal carriage and ISD surveillance, especially after complete eradication of pneumococcal vaccine serotypes and following implementation of broader-coverage pneumococcal conjugate vaccines in the population, needs to be implemented.

The long-term impact of PCV-7 implementation on nasopharyngeal carriage of *H. influenzae* and *M. catarrhalis* was also investigated. Two Finnish otitis media trials investigating a CRM197- or a OMPC-protein based PCV-7 in healthy infants noted an increase in either *H. influenzae* or *M. catarrhalis in middle-ear fluid during episodes of AOM, respectively [9,10]. Post-marketing observational studies in the USA reported relative increases in both *H. influenzae* and *M. catarrhalis* causing AOM in children after PCV-7 implementation [35,36].

Relatively high nasopharyngeal carriage rates of *H. influenzae* and *M. catarrhalis* were already observed before PCV-7 introduction in the Netherlands [37]. Nevertheless, we observed significant increases in *H. influenzae* carriage in children of both age groups as well in their parents both 3 and 4.5 years after introduction of PCV-7. Although no consistent changes in nasopharyngeal carriage of *H. influenzae* were observed by conventional culture techniques in a previous randomized controlled trial evaluating reduced-dose schedules of PCV-7 [37], a trend towards increased presence and abundance of *Haemophilus* species by molecular techniques was observed in PCV-7 vaccinated children compared with PCV-7 unvaccinated controls after 2+1 doses of PCV-7 (unpublished data). We therefore hypothesize that implementation of a full-dose schedule with 4 doses of PCV-7, together with continuing nationwide PCV-7 vaccine pressure, may have facilitated increased *H. influenzae* carriage in our study. In this study, we have not typed the recovered *H. influenzae* isolates. However, between 2008 and 2010, during the same period as the current study, we conducted a large randomized controlled trial in the same area in the Netherlands in which 780 infants were vaccinated with either CRM197-conjugated PCV-7 or Protein-D-conjugated PCV-10 with carriage of *H. influenzae as* endpoint. Similar to the present study, 65% of all cultured swabs were positive for *H. influenzae* based on conventional culture methods. After discrimination from *H. haemolyticus* by PCR, 92% were confirmed as *H. influenzae*. Of these, 8% were encapsulated strains; most frequently type a (5%) and f (1%) (unpublished data).

As for *M. catarrhalis*, no consistent changes in carriage after PCV-7 implementation were found, except for an increase in carriage in 24-month-old children and their parents 4.5 years post-PCV7. These results are in line with the randomized controlled trial which found no changes in *M. catarrhalis* carriage [37]. Again, bacterial interference, resource availability and host immunological factors may all play a role in the co-existence or competition between species in the nasopharynx, but the exact mechanisms of interactions are not yet fully elucidated [30].

With respect to the pneumococcal carriage surveillance study 4.5 years after PCV-7 introduction, we found that PCV-7-serotype pneumococci and cross-reactive serotype 6A were virtually eliminated among children and their parents. Simultaneously, non-PCV-7-serotypes increased significantly and showed higher diversity. Consistent with reports from other countries, 19A became the most predominant colonizing serotype in all investigated age groups in the Netherlands, followed by 6C, 15B/C and 11A [39,40]. Also in IPD, serotype 19A has increased significantly to become the fourth most frequently isolated serotype in the Netherlands after 7F, 1 and 8. Although frequently carried serotypes 6C, 15B/C and 11A are now also more frequently found in IPD, their total number of cases still remained low (unpublished data). However, due to the adaptive nature of the pneumococcus [41], long-term nasopharyngeal carriage and IPD surveillance in all age groups remain essential to evaluate health and economic impact in the future.

A limitation of the current observational study design is that we documented associations and no causalities between the introduction of PCV-7 and changes in nasopharyngeal bacterial carriage patterns. However, after correction for differences in measured potential confounders by using multivariate analysis, our results remained robust. Nonetheless, the impact of other unmeasured determinants such as the presence of viruses or climatologic factors cannot be excluded. Also, our results for *S. aureus* may have been underestimated due to sampling the nasopharyngeal niche rather than sampling the anterior nares, which is assumed the ecological site for *S. aureus* [14].

Strengths of our study are the consistency of our data measured in large cohorts at two sequential time points after PCV-7 implementation and compared to a historical baseline. Importantly, similar standard operating procedures were followed in the same laboratory for all three studies. Furthermore, we evaluated the impact of PCV-7 not only in vaccinated infants but also in unvaccinated adult contacts in a country with PCV-7 uptake of almost 95% in the NIP [10]. Finally, the studies were performed in a country with low antibiotic consumption and resistance rates and therefore unlikely to be confounded by antibiotic resistant clones [42].

In conclusion, next to large shifts in pneumococcal serotypes, we observed persistently higher carriage rates of *S. aureus* and *H. influenzae* after PCV-7 implementation in children at a young age vulnerable for bacterial infections as well as in parents. In addition to the need for ongoing surveillance of nasopharyngeal bacterial carriage over time, disease surveillance is warranted to verify potential clinical consequences of these findings.

### Supporting Information

#### Table S1

| Frequencies of nasopharyngeal carriage of individual *S. pneumoniae* serotypes in children and parents before, 3 and 4.5 years after PCV-7 implementation. |

(DOCX)

### Acknowledgments

We wish to thank all the members of the research team, the laboratory staff and the cooperating institutes for their dedication to the projects. Most of all, we are indebted to all the participating children and their families.

### Author Contributions

Conceived and designed the experiments: RHV AJWM GPJMD EAMS. Performed the experiments: JS SMPJP EJMG JPB. Analyzed the data: JS SMPJP EJMG RHV DB EAMS. Contributed reagents/materials/analysis tools: JPB. Drafted of the manuscript: JS SMPJP EJMG RHV EAMS. Contributed significantly to the final manuscript by critical revision for important intellectual content: JS SMPJP EJMG RHV DB AJWM GPJMD EAMS.

### References

1. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H (2006) Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 5: 631–667.

2. Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, et al. (2011) Carriage of *Streptococcus pneumoniae* 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis 17: 304–501.
